ibi376
Showing 1 - 2 of 2
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
- IBI376
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)
Recruiting
- Inert Non Hodgkin's Lymphoma
- IBI376
- Rituximab
-
Beijing, ChinaBiotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022